Prognostic significance of inflammatory biomarkers in hepatocellular carcinoma following hepatic resection

被引:63
作者
Itoh, S. [1 ]
Yugawa, K. [1 ]
Shimokawa, M. [1 ]
Yoshiya, S. [1 ]
Mano, Y. [1 ]
Takeishi, K. [1 ]
Toshima, T. [1 ]
Maehara, Y. [2 ]
Mori, M. [1 ]
Yoshizumi, T. [1 ]
机构
[1] Kyushu Univ, Grad Sch Med Sci, Dept Surg & Sci, Fukuoka, Fukuoka, Japan
[2] Kyushu Cent Hosp Mutual Aid Assoc Publ Sch Teache, Dept Surg, Fukuoka, Fukuoka, Japan
来源
BJS OPEN | 2019年 / 3卷 / 04期
关键词
TO-MONOCYTE RATIO; LYMPHOCYTE RATIO; SURVIVAL; CANCER; IMPACT; CHEMOTHERAPY; PROGRESSION; EXPRESSION; BLOCKADE; OUTCOMES;
D O I
10.1002/bjs5.50170
中图分类号
R61 [外科手术学];
学科分类号
摘要
Background Cancer-related inflammation has been correlated with cancer prognosis. This study evaluated inflammatory biomarkers, including neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR) and lymphocyte-to-monocyte ratio (LMR), programmed death ligand (PD-L) 1 expression, and tumour microenvironment in relation to prognosis and clinicopathological features of patients with hepatocellular carcinoma (HCC) undergoing curative hepatic resection. Methods Patients who had liver resection for HCC in 2000-2011 were analysed. Univariable and multivariable analyses were conducted for overall (OS) and recurrence-free (RFS) survival. Immunohistochemical analyses of PD-L1, CD8 and CD68 expression were performed. HCC cell lines were evaluated for PD-L1 expression. A subgroup analysis was conducted to determine patient features, survival and the tumour microenvironment. Results were validated in a cohort of patients with HCC treated surgically in 2012-2016. Results Some 281 patients who underwent hepatic resection for HCC were included. Multivariable analysis showed that low LMR was an independent prognostic factor of OS (hazard ratio (HR) 1.59, 95 per cent c.i. 1.00 to 2.41; P = 0.045) and RFS (HR 1.47, 1.05 to 2.04; P = 0.022) after resection. Low preoperative LMR values were correlated with higher alpha-fetoprotein values (P < 0.001), larger tumour size (P < 0.001), and high rates of poor differentiation (P = 0.035) and liver cirrhosis (P = 0.008). LMR was significantly lower in PD-L1-positive patients than in those with PD-L1 negativity (P < 0.001). Results were confirmed in the validation cohort. PD-L1 expression was upregulated in HCC cell lines treated with interferon-gamma and co-cultured with THP-1 monocyte cells. Conclusion LMR is an independent predictor of survival after hepatic resection in patients with HCC. Modulation of the immune checkpoint pathway in the tumour microenvironment is associated with a low LMR.
引用
收藏
页码:500 / 508
页数:9
相关论文
共 25 条
[1]   Hepatocellular carcinoma epidemiology [J].
Bosetti, Cristina ;
Turati, Federica ;
La Vecchia, Carlo .
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY, 2014, 28 (05) :753-770
[2]   Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].
Brahmer, Julie R. ;
Tykodi, Scott S. ;
Chow, Laura Q. M. ;
Hwu, Wen-Jen ;
Topalian, Suzanne L. ;
Hwu, Patrick ;
Drake, Charles G. ;
Camacho, Luis H. ;
Kauh, John ;
Odunsi, Kunle ;
Pitot, Henry C. ;
Hamid, Omid ;
Bhatia, Shailender ;
Martins, Renato ;
Eaton, Keith ;
Chen, Shuming ;
Salay, Theresa M. ;
Alaparthy, Suresh ;
Grosso, Joseph F. ;
Korman, Alan J. ;
Parker, Susan M. ;
Agrawal, Shruti ;
Goldberg, Stacie M. ;
Pardoll, Drew M. ;
Gupta, Ashok ;
Wigginton, Jon M. .
NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465
[3]   The Lymphocyte-to-Monocyte Ratio is a Superior Predictor of Overall Survival in Comparison to Established Biomarkers of Resectable Colorectal Cancer [J].
Chan, Joseph C. Y. ;
Chan, David L. ;
Diakos, Connie I. ;
Engel, Alexander ;
Pavlakis, Nick ;
Gill, Anthony ;
Clarke, Stephen J. .
ANNALS OF SURGERY, 2017, 265 (03) :539-546
[4]   Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial [J].
El-Khoueiry, Anthony B. ;
Sangro, Bruno ;
Yau, Thomas ;
Crocenzi, Todd S. ;
Kudo, Masatoshi ;
Hsu, Chiun ;
Kim, Tae-You ;
Choo, Su-Pin ;
Trojan, Jorg ;
Welling, Theodore H., III ;
Meyer, Tim ;
Kang, Yoon-Koo ;
Yeo, Winnie ;
Chopra, Akhil ;
Anderson, Jeffrey ;
dela Cruz, Christine ;
Lang, Lixin ;
Neely, Jaclyn ;
Tang, Hao ;
Dastani, Homa B. ;
Melero, Ignacio .
LANCET, 2017, 389 (10088) :2492-2502
[5]   Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms [J].
Elinav, Eran ;
Nowarski, Roni ;
Thaiss, Christoph A. ;
Hu, Bo ;
Jin, Chengcheng ;
Flavell, Richard A. .
NATURE REVIEWS CANCER, 2013, 13 (11) :759-771
[6]   Chemotherapy for hepatocellular carcinoma: current status and future perspectives [J].
Ikeda, Masafumi ;
Morizane, Chigusa ;
Ueno, Makoto ;
Okusaka, Takuji ;
Ishii, Hiroshi ;
Furuse, Junji .
JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2018, 48 (02) :103-114
[7]   Role of expression of focal adhesion kinase in progression of hepatocellular carcinoma [J].
Itoh, S ;
Maeda, T ;
Shimada, M ;
Aishima, S ;
Shirabe, K ;
Tanaka, S ;
Maehara, Y .
CLINICAL CANCER RESEARCH, 2004, 10 (08) :2812-2817
[8]   Role of growth factor receptor-bound protein 7 in hepatocellular carcinoma [J].
Itoh, Shinji ;
Taketomi, Akinobu ;
Tanaka, Shinji ;
Harimoto, Norifumi ;
Yamashita, Yo-ichi ;
Aishima, Shin-ichi ;
Maeda, Takashi ;
Shirabe, Ken ;
Shimada, Mitsuo ;
Maehara, Yoshihiko .
MOLECULAR CANCER RESEARCH, 2007, 5 (07) :667-673
[9]   Effect of Body Composition on Outcomes after Hepatic Resection for Hepatocellular Carcinoma [J].
Itoh, Shinji ;
Shirabe, Ken ;
Matsumoto, Yoshihiro ;
Yoshiya, Shohei ;
Muto, Jun ;
Harimoto, Norifumi ;
Yamashita, Yo-ichi ;
Ikegami, Toru ;
Yoshizumi, Tomoharu ;
Nishie, Akihiro ;
Maehara, Yoshihiko .
ANNALS OF SURGICAL ONCOLOGY, 2014, 21 (09) :3063-3068
[10]   Zero mortality in more than 300 hepatic resections: validity of preoperative volumetric analysis [J].
Itoh, Shinji ;
Shirabe, Ken ;
Taketomi, Akinobu ;
Morita, Kazutoyo ;
Harimoto, Norifumi ;
Tsujita, Eiji ;
Sugimachi, Keishi ;
Yamashita, Yo-ichi ;
Gion, Tomonobu ;
Maehara, Yoshihiko .
SURGERY TODAY, 2012, 42 (05) :435-440